Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-11-01

Clinical Trial Update: Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

Phase 3 trial update for SPIL1033 in type 2 diabetes mellitus reporting completed results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SPIL1033

Snippet

Sponsor: Sun Pharmaceutical Industries Limited | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2019-11-01